Next Article in Journal
HSP70 Gene Family in Brassica rapa: Genome-Wide Identification, Characterization, and Expression Patterns in Response to Heat and Cold Stress
Previous Article in Journal
The Role of Inflammatory Mediators in Colorectal Cancer Hepatic Metastasis
Previous Article in Special Issue
Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 11
Issue 15
10.3390/cells11152311
Review Report
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Article
Peer-Review Record

Kidney Cancer Biomarker Selection Using Regularized Survival Models

Cells 2022, 11(15), 2311; https://doi.org/10.3390/cells11152311
by Carolina Peixoto 1, Marta Martins 2, Luís Costa 2,3 and Susana Vinga 1,*
Reviewer 1:
Shu-Pin Huang
Reviewer 2: Anonymous
Cells 2022, 11(15), 2311; https://doi.org/10.3390/cells11152311
Submission received: 13 June 2022 / Revised: 8 July 2022 / Accepted: 13 July 2022 / Published: 27 July 2022
(This article belongs to the Special Issue Translational Oncobiology: From Molecular Mechanisms to Targeted Therapies)

Round 1

Reviewer 1 Report

This is an interesting study regarding the biomarkers for cRCC using RNA-seq data.

There are some comments:

1: Regarding the Table 1, what the treatment modalities for these RCC patients? Surgery, Target therapy ( like VEGF inhibitor: sutent and votrient) or Immunotherapy or combined Target therapy and immunotherrapy?

 since the effect of RNA expression profile on RCC survival may be different in RCC post surgery  or in metastasis RCC post sutent/votrient or other therapy

2: if majority of the table 1 RCC case receive surgery, could author find the RNA expression data of " metastatic" RCC who receive target therapy or immunotherapy, and re-analysis the impact on survival?

3: functional study may be needed, or discuss

    many biomarkers showed positive data, which one is more important, what the mechanism behind, through cell cycle regulators, metastasis, apoptosis?

4:  these prognostic biomarkers for RCC, is only for early /clinical localized RCC , or also good biomarkers for metastatic RCC?  why?

  

 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The paper by Peixoto et al is a study that identify potential prognostic biomarkers correlated to survival outcome of ccRCC patients using two network-based regularizers (EN and TCox) applied to Cox model.

The study is well performed and very well written. It is an important and interesting application of the how to better find and evaluate potential prognostic biomarkers correlated to survival outcome of ccRCC patients. The result section is described in a way which is very easy to follow. The discussion part mention the biological function of the genes of interest.

Indeed, the use of molecular profiling in cancer diagnostics has expanded. This is an important contribution to the field of kidney cancer research and ccRCC.

However, there are are some minor points that need to be considered:

-A language check is needed

-Key words are general

-References 1, 7 and 25 are old; from 2008 and 2010, respectively. Are there more updated references?

-Is there a reference to the sentence:  “Nowadays, there are no effective biomarkers for early diagnosis of RCC in clinical 36 treatment, and the molecular mechanism of RCC metastasis remains unclear" that can be added?

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Round 2

Reviewer 1 Report

The raised questions and the limitations of current study were answered adequately.

Back to TopTop